Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) has recently initiated the Phase I pharmacokinetic study designed to evaluate the safety, bioavailability and glucose response of Nastech's proprietary, rapid acting intranasal insulin formulation.
The Phase 1 study will compare Nastech's intranasal formulation to an approved injectable product and to a recently approved new dosage form, Exubera® (insulin human [rDNA origin]) Inhalation Powder.
Nastech's insulin nasal spray could provide patients with a convenient, needle-free alternative while avoiding possible pulmonary side effects or long term toxicity associated with the inhalation of insulin.
The said Phase 1 study is the first of the several studies that will select the formulation and determine the optimal insulin nasal spray dose that will be used to conduct subsequent safety and efficacy studies.
The Phase 1 study is designed as a dose ranging study in which subjects will receive a single subcutaneous injection of insulin, a single administration of Exubera®, and several different Nastech insulin nasal spray doses on separate days.
Find more details from the full press release.
Comment Preview